Sirona Biochem Engages Atheln Inc. to Strengthen Enterprise Progress Initiatives

VANCOUVER, British Columbia, May perhaps 25, 2023 (Globe NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is pleased to announce it has contracted Atheln Inc. (“Atheln“), a primary US consulting company, to bolster and facilitate Sirona’s business routines. This strategic initiative will come at an opportune time, as Sirona prepares for the extremely expected BIO Intercontinental 2023 meeting in Boston, where by it will showcase its groundbreaking anti-growing old compound, TFC-1326. Less than the steering of Monica Alfaro Welling, Atheln will spearhead the job staff to make sure the achievement of Sirona’s meetings through the meeting.

The key target of the agreement is to meticulously put together for the BIO Intercontinental convention, where by Sirona aims to build important partnerships for the progress and commercialization of TFC-1326. Recognizing the significance of these meetings, the collaboration with Atheln aims to optimize the likelihood of achievement. Sirona’s workforce has secured numerous meetings with businesses and corporations that have complementary resources, capabilities, and a strategic fascination in partnerships.

Sirona recognizes that productive conversation, extensive preparation, and a distinct value proposition significantly improve the probability of finding ideal companions for TFC-1326 at the BIO International conference.

Subsequent the conclusion of the BIO convention, Sirona will carry on to operate with Atheln to prolong its world wide outreach to organizations that did not show up at the party. By increasing endeavours to establish valuable connections and collaborations, Sirona aims to forge strategic alliances and broaden the reach of its ground breaking options.

About Monica Alfaro Welling, MBA – Commercial/Business enterprise Advancement

With above 30 many years of working experience in new merchandise setting up, strategic scheduling, portfolio examination, industry enhancement and product sales/marketing and advertising, company growth of prescription drugs, biotechnology, and professional medical equipment, Monica has experienced a distinctive job in the existence science field. She has been concerned in each and every part of the development and commercialization procedure of early and late-stage systems and new therapeutic programs. Monica has launched quite a few disruptive technologies such as BOTOXand been concerned in a selection of plans concentrating on the aesthetic market. Through her career, she has led advancement of business strategies which include positioning, messaging, KOL development, reimbursement strategies and scientific reports to help positioning. In addition, her encounter spans across a multitude of therapeutic spots such as dermatology (medical and aesthetics), oncology, ophthalmology, endocrinology, CNS, discomfort, habit, again agony, and orphan illnesses. As a result of her C-suite expertise and consulting, Monica has been associated in fundraising (community and personal) and licensing pursuits including profiling of prospective strategics, outreach and defining offer phrases. Prior to her consulting profession, she held govt and administration roles at Allergan, Novo Nordisk, and a commence-up enterprise. She has an MBA from Southern Danish College in Denmark, as perfectly as a BS in Biology and a BA in Economics from the University of California, Irvine.

About Atheln, Inc.

Atheln can help shoppers produce and execute integrated pharma and biotech products progress and commercialization methods. With a world staff of above 100 very specialised, industry-seasoned industry experts Atheln’s team excel at possibility identification and mitigation, whilst providing period correct and customized alternatives that optimize price and increase the chance of accomplishment for our consumers. For more data, remember to take a look at

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery organization with proprietary system technologies. Sirona specializes in stabilizing carbohydrate molecules with the target of enhancing efficacy and safety. New compounds are patented for utmost earnings potential.

Sirona’s compounds are accredited to main organizations all-around the planet in return for licensing expenses, milestone charges and ongoing royalty payments. Sirona’s laboratory, TFChem, is located an hour north of Paris, France and is the recipient of various French nationwide scientific awards and European Union and French govt grants. For additional information and facts, make sure you check out

BOTOX COSMETIC® is a registered trademark of Allergan, Inc.

For more facts pertaining to this press release, be sure to get in touch with:
Investor Enquiries:
E mail: [email protected]

Neither TSX Enterprise Trade nor its Regulation Expert services Provider (as that term is outlined in insurance policies of the TSX Venture Exchange) accepts obligation for the adequacy or accuracy of this launch.

Sirona Biochem cautions you that statements included in this press launch that are not a description of historical specifics could be forward-searching statements. Ahead-on the lookout statements are only predictions dependent upon existing expectations and entail identified and not known dangers and uncertainties. You are cautioned not to area undue reliance on these ahead-hunting statements, which talk only as of the day of launch of the applicable details, except if explicitly stated if not. True results, performance or accomplishment could differ materially from people expressed in, or implied by, Sirona Biochem’s ahead-searching statements due to the hazards and uncertainties inherent in Sirona Biochem’s organization together with, devoid of limitation, statements about: the progress and timing of its medical trials complications or delays in enhancement, testing, acquiring regulatory approval, generating and marketing and advertising its products and solutions unanticipated adverse aspect outcomes or inadequate therapeutic efficacy of its merchandise that could hold off or avoid product enhancement or commercialization the scope and validity of patent safety for its solutions competitors from other pharmaceutical or biotechnology organizations and its potential to acquire extra funding to support its functions. Sirona Biochem does not suppose any obligation to update any ahead-hunting statements besides as demanded by legislation.

Primary Logo

Source: Sirona Biochem Corp.

2023 GlobeNewswire, Inc., source Press Releases – Canada